{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:20:24Z","timestamp":1778905224994,"version":"3.51.4"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023MH029"],"award-info":[{"award-number":["ZR2023MH029"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.prp.2026.156407","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:03:17Z","timestamp":1771315397000},"page":"156407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma"],"prefix":"10.1016","volume":"281","author":[{"given":"Yuqing","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.prp.2026.156407_bib1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.prp.2026.156407_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.7150\/ijms.29935","article-title":"Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations","volume":"16","author":"Abdullah","year":"2019","journal-title":"Int J. Med Sci."},{"issue":"3","key":"10.1016\/j.prp.2026.156407_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"N. Cancer Genome Atlas Research","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156407_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107464","article-title":"RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma","volume":"167","author":"Hu","year":"2025","journal-title":"Oral. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib6","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0117","article-title":"RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis","volume":"30","author":"Bulanova Pekova","year":"2023","journal-title":"Endocr. Relat. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2026.156407_bib7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"13","key":"10.1016\/j.prp.2026.156407_bib8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/cncr.29044","article-title":"The RET oncogene in papillary thyroid carcinoma","volume":"121","author":"Prescott","year":"2015","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.prp.2026.156407_bib9","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1158\/1078-0432.CCR-20-1587","article-title":"Progresses Toward Precision Medicine in RET-altered Solid Tumors","volume":"26","author":"Belli","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"3-4","key":"10.1016\/j.prp.2026.156407_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000059341","article-title":"Conservation of RET proto-oncogene splicing variants and implications for RET isoform function","volume":"95","author":"Carter","year":"2001","journal-title":"Cytogenet Cell Genet"},{"issue":"3","key":"10.1016\/j.prp.2026.156407_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0006-291X(02)00886-0","article-title":"Differential interaction of Enigma protein with the two RET isoforms","volume":"296","author":"Borrello","year":"2002","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.prp.2026.156407_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103882","article-title":"Targeting RET alterations in cancer: Recent progress and future directions","volume":"181","author":"Shabbir","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000065725","article-title":"5'-End RET splicing: absence of variants in normal tissues and intron retention in pheochromocytomas","volume":"63","author":"Le Hir","year":"2002","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.prp.2026.156407_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10425170009033991","article-title":"cDNA sequence and genomic structure of the rat RET proto-oncogene","volume":"11","author":"Matera","year":"2000","journal-title":"DNA Seq."},{"issue":"10","key":"10.1016\/j.prp.2026.156407_bib15","first-page":"2039","article-title":"Characterization of RET proto-oncogene 3\u2032 splicing variants and polyadenylation sites: a novel C-terminus for RET","volume":"11","author":"Myers","year":"1995","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/ERC-16-0393","article-title":"Differential roles of RET isoforms in medullary and papillary thyroid carcinomas","volume":"24","author":"Lian","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib17","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1039\/C6CP00042H","article-title":"Defects in the calcium-binding region drastically affect the cadherin-like domains of RET tyrosine kinase","volume":"18","author":"Gao","year":"2016","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.prp.2026.156407_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47650","article-title":"Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands","volume":"8","author":"Li","year":"2019","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.prp.2026.156407_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.str.2020.12.012","article-title":"A two-site flexible clamp mechanism for RET-GDNF-GFRalpha1 assembly reveals both conformational adaptation and strict geometric spacing","volume":"29","author":"Adams","year":"2021","journal-title":"Structure"},{"issue":"7","key":"10.1016\/j.prp.2026.156407_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau4202","article-title":"Cryo-EM structure of the activated RET signaling complex reveals the importance of its cysteine-rich domain","volume":"5","author":"Bigalke","year":"2019","journal-title":"Sci. Adv."},{"issue":"53","key":"10.1016\/j.prp.2026.156407_bib21","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1038\/sj.onc.1209698","article-title":"Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations","volume":"25","author":"Kjaer","year":"2006","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib22","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.celrep.2016.11.061","article-title":"RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements","volume":"17","author":"Plaza-Menacho","year":"2016","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.prp.2026.156407_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.molcel.2014.01.015","article-title":"Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans","volume":"53","author":"Plaza-Menacho","year":"2014","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.prp.2026.156407_bib24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jfma.2025.06.033","article-title":"Four decades of the RET gene: From discovery to tumor-agnostic therapy","volume":"124","author":"Takahashi","year":"2025","journal-title":"J. Formos. Med Assoc."},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib25","doi-asserted-by":"crossref","first-page":"T79","DOI":"10.1530\/ERC-17-0354","article-title":"Structure and function of RET in multiple endocrine neoplasia type 2","volume":"25","author":"Plaza-Menacho","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"14","key":"10.1016\/j.prp.2026.156407_bib26","doi-asserted-by":"crossref","first-page":"14213","DOI":"10.1074\/jbc.M312600200","article-title":"Identification of RET autophosphorylation sites by mass spectrometry","volume":"279","author":"Kawamoto","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"38","key":"10.1016\/j.prp.2026.156407_bib27","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/sj.onc.1204715","article-title":"MEN2A-RET-induced cellular transformation by activation of STAT3","volume":"20","author":"Schuringa","year":"2001","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.prp.2026.156407_bib28","first-page":"3727","article-title":"Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival","volume":"60","author":"Vita","year":"2000","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.prp.2026.156407_bib29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1365-2796.2003.01167.x","article-title":"Cell signalling and gene expression mediated by RET tyrosine kinase","volume":"253","author":"Kurokawa","year":"2003","journal-title":"J. Intern Med"},{"issue":"39","key":"10.1016\/j.prp.2026.156407_bib30","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1038\/sj.onc.1203799","article-title":"Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor","volume":"19","author":"Hayashi","year":"2000","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.prp.2026.156407_bib31","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/sj.onc.1204290","article-title":"Identification of SNT\/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction","volume":"20","author":"Kurokawa","year":"2001","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1158\/0008-5472.CAN-06-0981","article-title":"RET\/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase","volume":"67","author":"De Falco","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.onc.1204049","article-title":"The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret","volume":"20","author":"Melillo","year":"2001","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1083\/jcb.200102032","article-title":"Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation","volume":"154","author":"Grimm","year":"2001","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41392-024-01742-2","article-title":"Docking protein 6 (DOK6) selectively docks the neurotrophic signaling transduction to restrain peripheral neuropathy","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"9","key":"10.1016\/j.prp.2026.156407_bib36","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1089\/thy.2019.0477","article-title":"Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma","volume":"30","author":"Dias-Santagata","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/cas.15181","article-title":"Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing","volume":"113","author":"Shi","year":"2022","journal-title":"Cancer Sci."},{"issue":"15","key":"10.1016\/j.prp.2026.156407_bib38","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1038\/onc.2009.502","article-title":"DNA breaks at fragile sites generate oncogenic RET\/PTC rearrangements in human thyroid cells","volume":"29","author":"Gandhi","year":"2010","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","article-title":"Genomic landscape of 891 RET fusions detected across diverse solid tumor types","volume":"7","author":"Parimi","year":"2023","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.prp.2026.156407_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102384","article-title":"The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis","volume":"55","author":"Zhao","year":"2025","journal-title":"Transl. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2017.0318","article-title":"Gene Fusions in Thyroid Cancer","volume":"28","author":"Yakushina","year":"2018","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.prp.2026.156407_bib42","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1016\/j.celrep.2016.08.019","article-title":"Drosophila cancer models identify functional differences between ret fusions","volume":"16","author":"Levinson","year":"2016","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib43","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood.V97.12.3910","article-title":"H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)","volume":"97","author":"Schwaller","year":"2001","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.prp.2026.156407_bib44","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1038\/sj.onc.1210446","article-title":"Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage","volume":"26","author":"Merolla","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"11","key":"10.1016\/j.prp.2026.156407_bib46","article-title":"Targeting the DNA damage response in cancer","volume":"5","author":"Federica","year":"2024","journal-title":"MedComm (2020)"},{"issue":"8","key":"10.1016\/j.prp.2026.156407_bib47","article-title":"Low-dose ionizing radiation-induced RET\/PTC1 rearrangement via the non-homologous end joining pathway to drive thyroid cancer","volume":"5","author":"Liu","year":"2024","journal-title":"MedComm (2020)"},{"issue":"7","key":"10.1016\/j.prp.2026.156407_bib48","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ijc.34396","article-title":"Adversary of DNA integrity: A long non-coding RNA stimulates driver oncogenic chromosomal rearrangement in human thyroid cells","volume":"152","author":"Demin","year":"2023","journal-title":"Int J. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2026.156407_bib49","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ijc.31106","article-title":"CCDC6: the identity of a protein known to be partner in fusion","volume":"142","author":"Cerrato","year":"2018","journal-title":"Int J. Cancer"},{"issue":"5935","key":"10.1016\/j.prp.2026.156407_bib50","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1126\/science.1172046","article-title":"Germline P granules are liquid droplets that localize by controlled dissolution\/condensation","volume":"324","author":"Brangwynne","year":"2009","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.prp.2026.156407_bib51","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.7150\/ijbs.92988","article-title":"The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers","volume":"20","author":"Xu","year":"2024","journal-title":"Int J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12943-025-02428-1","article-title":"Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities","volume":"24","author":"Hu","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib53","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41392-024-02013-w","article-title":"Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.prp.2026.156407_bib54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41568-022-00444-7","article-title":"Liquid-liquid phase separation drives cellular function and dysfunction in cancer","volume":"22","author":"Mehta","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"10.1016\/j.prp.2026.156407_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322359121","article-title":"CCDC6-RET fusion protein regulates Ras\/MAPK signaling through the fusion- GRB2-SHC1 signal niche","volume":"121","author":"Qiu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"16","key":"10.1016\/j.prp.2026.156407_bib56","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1038\/sj.onc.1209268","article-title":"Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET\/PTC rearrangements","volume":"25","author":"Gandhi","year":"2006","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/j.prp.2026.156407_bib57","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1007\/s00018-012-1000-y","article-title":"Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity","volume":"69","author":"Kollara","year":"2012","journal-title":"Cell Mol. Life Sci."},{"issue":"30","key":"10.1016\/j.prp.2026.156407_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2510269122","article-title":"Mechanistic insights into the iron-sulfur cluster-dependent interaction of the autophagy receptor NCOA4 with the E3 ligase HERC2","volume":"122","author":"Liu","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2026.156407_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-3-030-62026-4_4","article-title":"The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis","volume":"1301","author":"Santana-Codina","year":"2021","journal-title":"Adv. Exp. Med Biol."},{"issue":"10","key":"10.1016\/j.prp.2026.156407_bib60","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202203102","article-title":"NCOA4 drives ferritin phase separation to facilitate macroferritinophagy and microferritinophagy","volume":"221","author":"Ohshima","year":"2022","journal-title":"J. Cell Biol."},{"issue":"11","key":"10.1016\/j.prp.2026.156407_bib61","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1073\/pnas.93.11.5517","article-title":"Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells","volume":"93","author":"Yeh","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molcel.2014.04.031","article-title":"NCOA4 transcriptional coactivator inhibits activation of DNA replication origins","volume":"55","author":"Bellelli","year":"2014","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.prp.2026.156407_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111207","article-title":"NCOA4 links iron bioavailability to DNA metabolism","volume":"40","author":"Federico","year":"2022","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.prp.2026.156407_bib64","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.onc.1204127","article-title":"The RFG oligomerization domain mediates kinase activation and re-localization of the RET\/PTC3 oncoprotein to the plasma membrane","volume":"20","author":"Monaco","year":"2001","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.118535","article-title":"Iron homeostasis and oxidative stress: An intimate relationship","volume":"1866","author":"Galaris","year":"2019","journal-title":"Biochim Biophys. Acta Mol. Cell Res"},{"key":"10.1016\/j.prp.2026.156407_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5242437","article-title":"NCOA4: An Immunomodulation-Related Prognostic Biomarker in Colon Adenocarcinoma and Pan-Cancer","volume":"2022","author":"Gu","year":"2022","journal-title":"J. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156407_bib67","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40291-024-00721-1","article-title":"Papillary Thyroid Carcinoma: Correlation Between Molecular and Clinical Features","volume":"28","author":"Wang","year":"2024","journal-title":"Mol. Diagn. Ther."},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib68","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/s41379-020-0638-5","article-title":"Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization","volume":"33","author":"Chu","year":"2020","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2026.156407_bib69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00428-024-03777-w","article-title":"Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis","volume":"485","author":"Okubo","year":"2024","journal-title":"Virchows Arch."},{"issue":"10","key":"10.1016\/j.prp.2026.156407_bib70","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1089\/thy.2024.0151","article-title":"Clinicopathological Features of CCDC6-RET and NCOA4-RET Fusions in Thyroid Cancer: A Single-Center Retrospective Cohort Study in a Chinese Population","volume":"34","author":"Wang","year":"2024","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.prp.2026.156407_bib71","doi-asserted-by":"crossref","first-page":"e2737","DOI":"10.1210\/clinem\/dgae803","article-title":"Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma","volume":"110","author":"Chen","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13044-024-00209-4","article-title":"Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements","volume":"17","author":"Uno","year":"2024","journal-title":"Thyroid Res"},{"issue":"3","key":"10.1016\/j.prp.2026.156407_bib73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22229","article-title":"An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma","volume":"54","author":"Zhang","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.prp.2026.156407_bib74","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/1078-0432.CCR-20-3208","article-title":"A Performance Comparison of Commonly Used Assays to Detect RET Fusions","volume":"27","author":"Yang","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.prp.2026.156407_bib75","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1210\/clinem\/dgaa913","article-title":"Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma","volume":"106","author":"Liu","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.prp.2026.156407_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.prp.2026.156407_bib77","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/1078-0432.CCR-23-2693","article-title":"Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types","volume":"30","author":"Kasi","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.prp.2026.156407_bib78","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.CCR-21-2136","article-title":"The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib79","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1158\/1078-0432.CCR-24-3747","article-title":"Round-robin comparison of RET rearrangement detection in ctDNA: a novel method for limited clinical samples","volume":"31","author":"Paweletz","year":"2025","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib80","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2023.0204","article-title":"Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing","volume":"34","author":"Tarasova","year":"2024","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.prp.2026.156407_bib81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib82","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1507\/endocrj.EJ20-0171","article-title":"Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis","volume":"67","author":"Oba","year":"2020","journal-title":"Endocr. J."},{"issue":"9940","key":"10.1016\/j.prp.2026.156407_bib83","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.prp.2026.156407_bib84","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"17","key":"10.1016\/j.prp.2026.156407_bib85","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.prp.2026.156407_bib86","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40265-020-01343-7","article-title":"Selpercatinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"27","key":"10.1016\/j.prp.2026.156407_bib87","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib88","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in Patients with Advanced\/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.prp.2026.156407_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70042","article-title":"Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors","author":"Liu","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"issue":"8","key":"10.1016\/j.prp.2026.156407_bib90","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med"},{"issue":"9","key":"10.1016\/j.prp.2026.156407_bib91","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"18","key":"10.1016\/j.prp.2026.156407_bib92","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144847","article-title":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","volume":"131","author":"Lee","year":"2021","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.prp.2026.156407_bib93","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1097\/RLU.0000000000004475","article-title":"Reversing \"Flip-Flop\" Phenomenon of 131 I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib","volume":"48","author":"Chan","year":"2023","journal-title":"Clin. Nucl. Med"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib94","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib95","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12020-024-03890-5","article-title":"Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer","volume":"86","author":"Pitoia","year":"2024","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib96","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2026.156407_bib97","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib98","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41698-021-00188-x","article-title":"The L730V\/I RET roof mutations display different activities toward pralsetinib and selpercatinib","volume":"5","author":"Shen","year":"2021","journal-title":"NPJ Precis Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156407_bib99","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10637-022-01259-x","article-title":"The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046","volume":"40","author":"Repetto","year":"2022","journal-title":"Invest N. Drugs"},{"issue":"9","key":"10.1016\/j.prp.2026.156407_bib100","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2026.156407_bib101","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00053","article-title":"Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma","author":"Hadoux","year":"2023","journal-title":"JCO Precis Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib102","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0224","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2026.156407_bib103","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ando.2024.02.001","article-title":"RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions","volume":"85","author":"Hamidi","year":"2024","journal-title":"Ann. Endocrinol. (Paris)"},{"issue":"1","key":"10.1016\/j.prp.2026.156407_bib104","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2026.156407_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1264231","article-title":"Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: case report","volume":"13","author":"Leite","year":"2023","journal-title":"Front Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:25:33Z","timestamp":1774121133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":105,"alternative-id":["S0344033826000580"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156407","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156407"}}